


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



Complete if Known

Application Number	10/626,827
Filing Date	July 23, 2003
First Named Inventor	Theodore O. Johnson, Jr.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	0055-01-US

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
FTP	AA	5,856,530	01-05-1999	Agouron Pharmaceuticals, Inc. <i>Webber et al</i>	
FTP	AB	5,962,487	10-05-1999	Agouron Pharmaceuticals, Inc. <i>Webber et al</i>	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FTP	AC	BIRCH, G. et al., "Purification Of Recombinant Human Rhinovirus 14 3C Protease Expressed In Escherichia Coli" <i>Protein Expression And Purification</i> 1995, 609-618, vol. 6.	
FTP	AD	BUNDGAARD, H. et al., <i>Design of Prodrugs</i> , 1985, Elsevier Press.	
FTP	AE	DIANA, G. et al., "Picornavirus Inhibitors: Trifluoromethyl Substitution Provides A Global Protective Effect Against Hepatic Metabolism" <i>J. Med. Chem.</i> 1995, 1355-1371, Vol. 38.	
FTP	AF	DRAGOVICH, P. et al., "Solid-Phase Synthesis Of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 1: Optimization Of Tripeptides Incorporating N-Terminal Amides" <i>Bioorganic & Medicinal Chemistry</i> 1999, 589-598, vol. 7.	
FTP	AG	DRAGOVICH, P. et al., "Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure-Activity Studies Of Ketomethylene-Containing Peptidomimetics" <i>J. Med. Chem.</i> 1999, 1203-1212, vol. 42.	

EXAMINER:

Kevin T. Powers

DATE CONSIDERED:

2/5/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/626,827
Filing Date	July 23, 2003
First Named Inventor	Theodore O. Johnson, Jr.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	0055-01-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

LTP	AH	DRAGOVICH, P. et al., "Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P ₁ Lactam Moieties as L-Glutamine Replacements," J. Med. Chem. 1999, 1213-1224, vol. 42.
LTP	AI	WEISLOW, et al., J. Natl. Cancer Inst. 1989, 577-586, vol. 81.
		/

EXAMINER:

Fiona T. Powers

DATE CONSIDERED:

2/5/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**